Neo-Sequence 1: Neoadjuvant Chemotherapy With or Without Antiangiogenesis and Sequential Immunotherapy for HER2-negative MMR-proficient Locally Advanced Gastric or Gastroesophageal Adenocarcinoma

NCT05540145 · clinicaltrials.gov ↗

COMPLETED

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer

Interventions

DRUG: SOX plus Paclitaxel with or without antiangiogenesis followed by PD-1 antibody

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences